To test the potential of KIF2C as a therapeutic target in the treatment of HCC, we evaluated the impact of silencing or overexpressing KIF2C on the efficacy of the mTOR inhibitor INK128. The gene discussed is MTOR; the disease is hepatocellular carcinoma.